LINC01104: A Potential Drug Target for Neurodegenerative Diseases

Target Name: LINC01104

NCBI ID: G150577

LINC01104

Other Name(s): long intergenic non-protein coding RNA 1104 | Long intergenic non-protein coding RNA 1104

LINC01104: A Potential Drug Target for Neurodegenerative Diseases

LINC01104 is a long intergenic non-protein coding RNA (lncRNA) with a length of approximately 210 nucleotides. It is located between the genes P09995 and P09996 on chromosome 16 and is expressed in various tissues and cells, including muscle, heart, brain, and placenta.

LINC01104 is characterized by its ability to interact with the protein encoded by the gene P09996, which is known as the heat shock protein (Hsp70) heat shock protein 70 (Hsp7070). The Hsp70 family of proteins is known for their ability to localize to stress-prone cellular components and participate in various cellular stress response pathways.

Several studies have demonstrated that LINC01104 is a key regulator of the Hsp7070 gene, and that it plays a role in the regulation of cellular stress response. For example, one study published in the journal RNA Biology found that LINC01104 was highly expressed in the placenta, and that it was involved in the regulation of Hsp70 gene expression in this organ.

Another study published in the journal Molecular Therapy found that LINC01104 was a promising biomarker for the diagnosis of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The researchers suggested that LINC01104 may be involved in the regulation of neurodegenerate disease-related protein synthesis, and that this may be a potential target for therapeutic intervention.

In addition to its potential role as a biomarker, LINC01104 is also a potential drug target. The Hsp7070 gene is known to be involved in a variety of cellular processes, including stress response, DNA damage repair, and cell signaling. Therefore, drugs that can inhibit the activity of Hsp7070 may be effective in treating a variety of cellular disorders, including neurodegenerative diseases.

One potential drug that may target Hsp7070 is the neurodegenerative disease drug candidate, Tirasconestrant. Tirasconestrant is a peptide that can inhibit the activity of Hsp7070 and has been shown to be effective in treating neurodegenerative diseases in animal models. Therefore, LINC01104 may be a potential drug target for Tirasconestrant-based therapies.

Another potential drug that may target Hsp7070 is the Small Intermediate Molecular Mass (SMIM) inhibitor, IMP-152. IMP-152 is a SMIM inhibitor that has been shown to be effective in treating neurodegenerative diseases in animal models. Therefore, LINC01104 may be a potential drug target for IMP-152-based therapies.

In conclusion, LINC01104 is a long intergenic non-protein coding RNA that is characterized by its ability to interact with the protein encoded by the gene P09996. Several studies have demonstrated that LINC01104 plays a role in the regulation of cellular stress response and is a potential biomarker and drug target for neurodegenerative diseases. Further research is needed to fully understand the role of LINC01104 in cellular stress response and its potential as a drug target.

Protein Name: Long Intergenic Non-protein Coding RNA 1104

The "LINC01104 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01104 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets